eLetters

197 e-Letters

published between 2006 and 2009

  • Antithrombotic treatment in atrial fibrillation
    Oscar, M Jolobe

    Dear Editor,

    Given the fact that BAATAF conferred a relative risk reduction of 86%, and SPINAF conferred a relative risk reduction of 79% for embolic complications of non valvular atrial fibrillation(NVAF) utilising INR ranges of 1.5-2.7, and 1.4-2.8, respectively(1)(2), in a population presumably comprising, not only NVAF patients at high risk of embolic complications, but also those at low risk, the hypothesis...

    Show More
  • Use of nicotinic acid in JBS2
    Tony Patrikios

    Dear Editor,

    With interest we read the new JSB guidelines but would like to clarify an issue relating to the correct licensed indication for nicotinic acid. Table 11 of the guidelines specifies that nicotinic acid be used in severe hypertriglyceridaemia with prior acute pancreatitis or not responsive to fibrates. The only formulation of nicotinic acid licensed for the treatment of dyslipidaemia is the prolonged re...

    Show More
  • Possible interactions of air pollution and acute respiratory infections in the triggering of AMI
    Viktor Èuliæ

    Dear Editor,

    Respiratory tract infection has been implicated as a factor leading to the onset of acute myocardial infarction. In contrast to previous data,[1] Clayton et al.[2] did not observe a significant association between recent respiratory infection and myocardial infarction, but they did find a strong association of infarction with chest pain on breathing within the preceding week or with fever.

    In...

    Show More
  • Late stent thrombosis in Sirolimus stents - not as rare as one imagines!
    Austin Mohan Komaranchath

    Dear Editor,

    We recently came across a similar patient who had a Sirolimus eluting stent implanted in his LAD in June 2004 and returned to us with an anterior wall myocardial infarction on the 2nd of January 2006.He had taken Aspirin and Clopidogrel for 10 months and then had switched to lower dose Aspirin (150mg to 80 mg)and stopped the Clopidogrel. He developed symptoms of angina during a flight back to India from...

    Show More
  • Comment on heart analyses
    AD Tsakok

    Dear Editor,

    Biagini et al (1), Rodriguez et al (2) and Dursunglu et al (3) illustrate incorrect statistical analyses, by using the two-sample t-test. This compares normal means assuming unknown but equal variances. While the Central Limit Theorem justifies normality for mean inferences, making it unnecessary to test (3) for normality, unknown variances need not be homogeneous. This makes the two-sample t-test un...

    Show More
  • Dark chocolate and cardiovascular health
    Nir Barak

    Dear Editor,

    I read with great interest the letter by Hermann et al.[1] regarding dark chocolate and endothelial dysfunction. The authors conclude "a small daily treat of dark chocolate may substantially increase the amount of antioxidant intake and beneficially effect vascular health".

    Unfortunately, not many people are aware of the possible toxic effects of dark chocolate: apart from its content of flavan...

    Show More
  • Prognosis of patients with silent versus symptomatic myocardial ischemia
    Don Poldermans

    Dear Editor,

    We do appreciate Dr Tsakok's concern regarding the correct use of the two-sample-t-test. At our centre it is common use to apply the Kolmogorv-Smirnov test to test the normality assumption in all our analyses. In our study this test was not significant and therefore, we were allowed to use the parametric tests such as the two sample t-test. The method Dr Tsakok is proposing is unknown to us. We are not...

    Show More

Pages